Index of reports
> Cases with Neutropenia (184)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine where reactions include neutropenia. The selected reports were submitted to the FDA during the sample period of about a year.
Reports 1 - 30 of 184 Next >>
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-27
Patient:
Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection
Drug(s) suspected as cause:
Carboplatin
Dosage: 6 courses in high risk
Indication: Retinoblastoma
Cyclophosphamide
Indication: Retinoblastoma
Doxorubicin Hydrochloride
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Etoposide
Indication: Retinoblastoma
Vincristine
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Other drugs received by patient: Neupogen
Possible Vincristine side effects in female
Reported by a physician from Thailand on 2012-08-24
Patient: female, weighing 57.4 kg (126.3 pounds)
Reactions: Neutropenia
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Start date: 2012-03-02
Doxorubicin Hydrochloride
Indication: B-Cell Lymphoma
Start date: 2012-03-02
Mabthera
Indication: B-Cell Lymphoma
Start date: 2012-03-02
Prednisone TAB
Indication: B-Cell Lymphoma
Start date: 2012-03-02
Vincristine
Indication: B-Cell Lymphoma
Start date: 2012-03-02
Other drugs received by patient: Dexamethasone; Acetaminophen; Ondansetron; Metformin HCL; Ondansetron; Ondansetron; Atenolol; Simvastatin; Benadryl
Possible Vincristine side effects in 52 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-24
Patient: 52 year old female
Reactions: Tumour Lysis Syndrome, Posterior Reversible Encephalopathy Syndrome, Insomnia, Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: according to larson regimen
Indication: B Precursor Type Acute Leukaemia
Daunorubicin HCL
Dosage: according to larson regimen
Indication: B Precursor Type Acute Leukaemia
Daunorubicin HCL
Dosage: at 50% dosage
Dexamethasone
Indication: Premedication
Methylprednisolone Sodium Succinate
Indication: B Precursor Type Acute Leukaemia
Prednisone TAB
Dosage: according to larson regimen
Indication: B Precursor Type Acute Leukaemia
Vincristine
Dosage: according to larson regimen
Indication: B Precursor Type Acute Leukaemia
Other drugs received by patient: Ondansetron; Voriconazole; Morphine Sulfate; Morphine
Possible Vincristine side effects in male
Reported by a physician from Germany on 2012-08-24
Patient: male
Reactions: Febrile Neutropenia, Skin Infection, Neutropenia, Pneumonitis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1500 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-02-02
End date: 2012-04-17
Doxorubicin Hydrochloride
Dosage: 100 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-02-02
End date: 2012-04-17
Neulasta
Dosage: 6 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-02-06
End date: 2012-04-20
Prednisolone
Dosage: 100 mg, unk
Administration route: Oral
Indication: B-Cell Lymphoma
Start date: 2012-02-02
End date: 2012-04-21
Rituximab
Dosage: 750 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-02-01
End date: 2012-04-16
Vincristine
Dosage: 2 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-02-02
End date: 2012-04-17
Other drugs received by patient: MST / 00036302 /; Novalgin / 00169801 /; Rulid; Pantoprazole; Paspertin / 00041902 /; Acyclovir; Electrolytes NOS W / Macrogol 3350; Dipyrone INJ; Metoclopramide; Acyclovir
Possible Vincristine side effects in 17 year old male
Reported by a physician from Poland on 2012-08-23
Patient: 17 year old male
Reactions: Rhabdomyolysis, Disseminated Intravascular Coagulation, Pancytopenia, Pyrexia, Renal Failure, Neutropenia, Clostridial Infection, Septic Shock
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cefepime
Doxorubicin Hydrochloride
Indication: Ewing's Sarcoma
Etoposide
Indication: Ewing's Sarcoma Metastatic
Ifosfamide
Indication: Ewing's Sarcoma Metastatic
Meropenem
Metronidazole
Netromycin
Vancocin Hydrochloride
Vincristine
Indication: Ewing's Sarcoma Metastatic
Other drugs received by patient: Fluconazole; Caspofungin Acetate
Possible Vincristine side effects in male
Reported by a physician from United States on 2012-08-22
Patient: male, weighing 55.2 kg (121.4 pounds)
Reactions: Unresponsive To Stimuli, Moaning, Neutropenia, Septic Shock, Cardiac Arrest
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Mercaptopurine
Start date: 2009-08-21
Methotrexate Sodium
Prednisone
Vincristine
End date: 2012-08-10
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-21
Patient:
Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection
Drug(s) suspected as cause:
Carboplatin
Dosage: 6 courses in high risk
Indication: Retinoblastoma
Cyclophosphamide
Indication: Retinoblastoma
Doxorubicin HCL
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Etoposide
Indication: Retinoblastoma
Vincristine
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Other drugs received by patient: Neupogen
Possible Vincristine side effects in female
Reported by a physician from United States on 2012-08-20
Patient: female, weighing 70.8 kg (155.8 pounds)
Reactions: Abdominal Pain, Hyperpyrexia, Anaphylactic Reaction, Chills, Pain, Hepatic Failure, Transaminases Increased, Splenic Infarction, Loss of Consciousness, Aortic Thrombosis, Off Label Use, Malaise, C-Reactive Protein Increased, Myositis, Dyspnoea, Hypotension, Arrhythmia, Lung Consolidation, Hypophosphataemia, Zygomycosis, Bacteraemia, Ventricular Tachycardia, Hyperammonaemia, Neutropenia, Hepatic Infarction, Shock, Infusion Related Reaction
Adverse event resulted in: death, life threatening event
Drug(s) suspected as cause:
Cytarabine
Dosage: day 1,8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
Decadron Phosphate
Dosage: day 1
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
Doxil
Dosage: day 1
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
End date: 2007-10-23
Methotrexate
Dosage: day 1
Indication: Acute Lymphocytic Leukaemia
Start date: 2005-01-01
End date: 2007-01-01
PEG-Asparaginase
Dosage: day 2, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-25
End date: 2007-10-25
Velcade
Dosage: day 1, 4, 8 and 11
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
End date: 2007-10-23
Vincristine
Dosage: day 1,8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
End date: 2007-10-23
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-16
Patient:
Reactions: Nausea, Pain, Motor Dysfunction, Rash, Peripheral Sensory Neuropathy, Fatigue, Blood Potassium Decreased, Dyspepsia, Diarrhoea, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Cyclophosphamide
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: B-Cell Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin HCL
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin HCL
Dosage: on day 1
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Waldenstrom's Macroglobulinaemia
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphocytic Lymphoma
Rituximab
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Indication: Lymphocytic Lymphoma
Rituximab
Dosage: maintenance
Indication: B-Cell Lymphoma
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Rituximab
Dosage: maintenance
Indication: Lymphoma
Rituximab
Dosage: on day 1
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: B-Cell Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Waldenstrom's Macroglobulinaemia
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: Lymphocytic Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Waldenstrom's Macroglobulinaemia
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: B-Cell Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphocytic Lymphoma
Other drugs received by patient: Acetaminophen; Diphenhydramine Hydrochloride; Ondansetron
Possible Vincristine side effects in female
Reported by a physician from United States on 2012-08-14
Patient: female, weighing 70.8 kg (155.8 pounds)
Reactions: Abdominal Pain, Rhabdomyolysis, Hyperpyrexia, Chills, Anaphylactic Reaction, Bone Pain, Hepatic Failure, Transaminases Increased, Loss of Consciousness, Aortic Thrombosis, Splenic Infarction, Hypokalaemia, Malaise, C-Reactive Protein Increased, Dyspnoea, Hypotension, Hypophosphataemia, Zygomycosis, Bacteraemia, Hyperammonaemia, Neutropenia, Hepatic Infarction, Lung Infiltration, Shock, Infusion Related Reaction
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Cytarabine
Dosage: 70 mg, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2005-01-01
End date: 2007-10-23
Decadron Phosphate
Dosage: 9 mg, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
End date: 2007-10-23
Doxorubicin HCL
Dosage: 107 mg, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
End date: 2007-10-23
Methotrexate Sodium
Dosage: unk, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2005-01-01
End date: 2007-01-01
Pegaspargase
Dosage: unk, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-25
Velcade
Dosage: 1.3 mg/m2, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
End date: 2007-10-23
Vincristine
Dosage: 2 mg, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
End date: 2007-10-23
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-07
Patient:
Reactions: Hospitalisation, Neuropathy Peripheral, Vomiting, Febrile Neutropenia, Neutropenia, Neutrophil Count Decreased, Lymphoma
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin Hydrochloride
Indication: B-Cell Lymphoma
Doxorubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Prednisone
Dosage: for 5 days
Indication: B-Cell Lymphoma
Prednisone
Dosage: for 5 days
Indication: Diffuse Large B-Cell Lymphoma
Radiotherapy
Indication: Diffuse Large B-Cell Lymphoma
Radiotherapy
Indication: B-Cell Lymphoma
Rituximab
Indication: B-Cell Lymphoma
Rituximab
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Other drugs received by patient: Neupogen
Possible Vincristine side effects in 76 year old
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-02
Patient: 76 year old
Reactions: Lung Disorder, Neutropenia, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Prednisone
Dosage: daily for 5 days
Indication: Diffuse Large B-Cell Lymphoma
Radiotherapy
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Other drugs received by patient: Neupogen
Possible Vincristine side effects in 58 year old male
Reported by a health professional (non-physician/pharmacist) on 2012-08-02
Patient: 58 year old male, weighing 77.0 kg (169.4 pounds)
Reactions: Haemoglobin Decreased, White Blood Cell Count Decreased, Platelet Count Decreased, Neutropenia
Drug(s) suspected as cause:
Asparaginase (Unspecified) (Asparginase) (Unknown)
Indication: Chemotherapy
Start date: 2012-03-12
Cyclophosphamide
Indication: Chemotherapy
Start date: 2012-03-12
Dexamethasone
Indication: Chemotherapy
Start date: 2012-03-12
Doxorubicin HCL
Indication: Chemotherapy
Start date: 2012-03-12
Isavuconazole (Isavuconazole)
Dosage: three times daily, intravenous (not otherwise specified)
Indication: Fungal Infection
Start date: 2012-02-07
End date: 2012-02-09
Vincristine
Indication: Chemotherapy
Start date: 2012-03-12
Other drugs received by patient: Metronidazole; Ciprofloxacin
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-01
Patient:
Reactions: Nausea, Motor Dysfunction, Pain, Rash, Peripheral Sensory Neuropathy, Fatigue, Dyspepsia, Blood Potassium Decreased, Diarrhoea, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Cyclophosphamide
Dosage: on day 1
Indication: B-Cell Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Cyclophosphamide
Dosage: on day 1
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: B-Cell Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Waldenstrom's Macroglobulinaemia
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphocytic Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: maintenance
Indication: Waldenstrom's Macroglobulinaemia
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Rituximab
Dosage: on day 1
Indication: B-Cell Lymphoma
Rituximab
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Indication: Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: non-Hodgkin's Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: B-Cell Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: Lymphocytic Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Waldenstrom's Macroglobulinaemia
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Waldenstrom's Macroglobulinaemia
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphocytic Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: B-Cell Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphoma
Other drugs received by patient: Diphenhydramine HCL; Acetaminophen; Ondansetron
Possible Vincristine side effects in
Reported by a physician from United Kingdom on 2012-08-01
Patient:
Reactions: Neutropenia, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1440 mg, unk
Indication: Mantle Cell Lymphoma
Doxorubicin Hydrochloride
Dosage: 96 mg, unk
Indication: Mantle Cell Lymphoma
Prednisone
Dosage: 100 mg, unk
Indication: Mantle Cell Lymphoma
Prednisone
Dosage: 80 unk, unk
Velcade
Dosage: 3 mg, unk
Indication: Mantle Cell Lymphoma
Start date: 2011-01-27
Vincristine
Indication: Mantle Cell Lymphoma
Other drugs received by patient: Sando K / 00031402 /
Possible Vincristine side effects in 17 year old male
Reported by a physician from Poland on 2012-08-01
Patient: 17 year old male
Reactions: Renal Failure, Rhabdomyolysis, Disseminated Intravascular Coagulation, Pancytopenia, Neutropenia, Clostridial Infection, Septic Shock
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Doxorubicin Hydrochloride
Indication: Ewing's Sarcoma
Etoposide
Indication: Ewing's Sarcoma Metastatic
Ifosfamide
Indication: Ewing's Sarcoma Metastatic
Vincristine
Indication: Ewing's Sarcoma Metastatic
Possible Vincristine side effects in male
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-08-01
Patient: male
Reactions: Neutropenia
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin Hydrochloride
Indication: B-Cell Lymphoma
Mabthera
Indication: B-Cell Lymphoma
Prednisone
Indication: B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from Russian Federation on 2012-07-31
Patient:
Reactions: Vomiting, Acute Leukaemia, Febrile Neutropenia, Treatment Failure, Neutropenia, Toxicity To Various Agents, Neoplasm, Leukopenia
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: as part of abvd or beacopp
Indication: Hodgkin's Disease
Chemoradiation
Indication: Hodgkin's Disease
Cyclophosphamide
Indication: Hodgkin's Disease
Dacarbazine
Indication: Hodgkin's Disease
Doxorubicin Hydrochloride
Dosage: as part of abvd or beacopp
Indication: Hodgkin's Disease
Etoposide
Indication: Hodgkin's Disease
Prednisone
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Indication: Hodgkin's Disease
Vinblastine Sulfate
Indication: Hodgkin's Disease
Vincristine
Indication: Hodgkin's Disease
Possible Vincristine side effects in female
Reported by a physician from United Kingdom on 2012-07-27
Patient: female, weighing 53.0 kg (116.6 pounds)
Reactions: Anaemia, Neutropenia, Hypokalaemia
Adverse event resulted in: life threatening event
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-12-23
Doxorubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-12-23
Furosemide
Prednisone
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-12-23
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-12-23
Possible Vincristine side effects in 17 year old male
Reported by a physician from Poland on 2012-07-27
Patient: 17 year old male
Reactions: Renal Failure, Rhabdomyolysis, Disseminated Intravascular Coagulation, Pancytopenia, Neutropenia, Septic Shock, Clostridial Infection
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Doxorubicin Hydrochloride
Indication: Ewing's Sarcoma
Etoposide
Indication: Ewing's Sarcoma Metastatic
Ifosfamide
Indication: Ewing's Sarcoma Metastatic
Vincristine
Indication: Ewing's Sarcoma Metastatic
Possible Vincristine side effects in
Reported by a physician from Italy on 2012-07-27
Patient:
Reactions: Anaemia, Skin Toxicity, Febrile Neutropenia, Mucosal Inflammation, Neurotoxicity, Respiratory Failure, Sepsis, Neutropenia, Cardiotoxicity, Septic Shock, Thrombocytopenia, Myocardial Infarction, Diffuse Large B-Cell Lymphoma
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Indication: Diffuse Large B-Cell Lymphoma
Epirubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Mabthera
Indication: Diffuse Large B-Cell Lymphoma
Prednisone and Prednisone
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from Russian Federation on 2012-07-26
Patient:
Reactions: Vomiting, Acute Leukaemia, Febrile Neutropenia, Treatment Failure, Neutropenia, Toxicity To Various Agents, Neoplasm, Leukopenia
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: as part of abvd or beacopp
Indication: Hodgkin's Disease
Chemoradiation
Indication: Hodgkin's Disease
Cyclophosphamide
Indication: Hodgkin's Disease
Dacarbazine
Indication: Hodgkin's Disease
Doxorubicin Hydrochloride
Dosage: as part of abvd or beacopp
Indication: Hodgkin's Disease
Etoposide
Indication: Hodgkin's Disease
Prednisone
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Indication: Hodgkin's Disease
Vinblastine Sulfate
Indication: Hodgkin's Disease
Vincristine
Indication: Hodgkin's Disease
Possible Vincristine side effects in
Reported by a physician from United Kingdom on 2012-07-25
Patient:
Reactions: Neutropenia, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1440 mg, unk
Indication: Mantle Cell Lymphoma
Doxorubicin Hydrochloride
Dosage: 96 mg, unk
Indication: Mantle Cell Lymphoma
Prednisone
Dosage: 80 unk, unk
Prednisone
Dosage: 100 mg, unk
Indication: Mantle Cell Lymphoma
Velcade
Dosage: 3 mg, unk
Indication: Mantle Cell Lymphoma
Start date: 2011-01-27
Vincristine
Indication: Mantle Cell Lymphoma
Other drugs received by patient: Sando K / 00031402 /
Possible Vincristine side effects in
Reported by a physician from Italy on 2012-07-20
Patient:
Reactions: Anaemia, Febrile Neutropenia, Toxicity To Various Agents, Diffuse Large B-Cell Lymphoma Recurrent, Mucosal Inflammation, Neurotoxicity, Sepsis, Adverse Event, Cardiotoxicity, Neutropenia, Thrombocytopenia, Diffuse Large B-Cell Lymphoma, Lymphoma, Septic Shock
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 750 mg/m2 on day 1 for chop and 750 mg/m2 on day 2 for r-chop
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: 50 mg/m2 on day 1 for chop and 50 mg/m2 on day 2 for r-chop
Indication: Diffuse Large B-Cell Lymphoma
Prednisone
Dosage: 100 mg on days 1-5 for chop and r-chop
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: 375 mg/m2 on day 1 for r-chop
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: 1.4 mg/m2 on day 1 for chop and 1.4 mg/m2 on day 2 for r-chop upto a maximum dose of 2 mg
Indication: Diffuse Large B-Cell Lymphoma
Other drugs received by patient: Neupogen
Possible Vincristine side effects in
Reported by a physician from United Kingdom on 2012-07-19
Patient:
Reactions: Neutropenia, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1440 mg, unk
Indication: Mantle Cell Lymphoma
Doxorubicin HCL
Dosage: 96 mg, unk
Indication: Mantle Cell Lymphoma
Prednisone
Dosage: 100 mg, unk
Indication: Mantle Cell Lymphoma
Prednisone
Dosage: 80 unk, unk
Velcade
Dosage: 3 mg, unk
Indication: Mantle Cell Lymphoma
Start date: 2011-01-27
Vincristine
Indication: Mantle Cell Lymphoma
Other drugs received by patient: Sando K / 00031402 /
Possible Vincristine side effects in male
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-07-18
Patient: male
Reactions: Neutropenia
Drug(s) suspected as cause:
Cyclophosphamide
Doxorubicin HCL
Mabthera
Indication: B-Cell Lymphoma
Prednisone
Vincristine
Possible Vincristine side effects in
Reported by a physician from Japan on 2012-07-17
Patient:
Reactions: Neuropathy Peripheral, Interstitial Lung Disease, Neutropenia, Infection
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin HCL
Indication: B-Cell Lymphoma
Neupogen
Indication: B-Cell Lymphoma
Prednisolone
Indication: B-Cell Lymphoma
Rituxan
Dosage: 6 doses-2 days prior to each cycle of chop
Indication: B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Possible Vincristine side effects in 18 year old male
Reported by a physician from Canada on 2012-07-17
Patient: 18 year old male
Reactions: Bronchopulmonary Aspergillosis, Aspergillosis, Arthritis Bacterial, Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Acute Lymphocytic Leukaemia
Daunorubicin HCL
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in male
Reported by a physician from Germany on 2012-07-16
Patient: male
Reactions: Neutropenia, Lymphocytic Infiltration
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Start date: 2012-04-17
End date: 2012-04-17
Doxorubicin HCL
Indication: B-Cell Lymphoma
Start date: 2012-04-17
End date: 2012-04-17
Mabthera
Indication: B-Cell Lymphoma
Start date: 2012-04-16
End date: 2012-04-16
Neulasta
Indication: B-Cell Lymphoma
Start date: 2012-04-20
End date: 2012-04-20
Prednisolone
Administration route: Oral
Indication: B-Cell Lymphoma
Start date: 2012-04-16
End date: 2012-04-21
Vincristine
Indication: B-Cell Lymphoma
Start date: 2012-04-17
End date: 2012-04-17
Other drugs received by patient: Metoclopramide; Morphine Sulphate Drip; Acyclovir; Dipyrone TAB; Pantoprazole
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-07-13
Patient:
Reactions: Neuropathy Peripheral, Neutropenia, Infection, Infusion Related Reaction
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: 6-821 day cycles; n=28
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: 6-821 day cycles; n=28
Obinutuzumab
Indication: B-Cell Lymphoma
Prednisone
Indication: B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Page 1 Next >>
|